OptimizeRx Corporation - OPRX STOCK NEWS

OptimizeRx Corp (Nasdaq: OPRX) announced its participation in three upcoming conferences this September. Management will attend the R.W. Baird Healthcare Conference in New York City on September 13, the Lake Street BIG6 Investor Conference on September 14, and the LifeSci Health Tech Symposium virtually on September 21. Presentations will cover the company's innovative point-of-care technology solutions aimed at helping patients manage their therapies. Interested parties can request in-person meetings through designated contacts.

OptimizeRx Corp (Nasdaq: OPRX) reports a successful case study highlighting its patent-pending real-world evidence solution, which identifies healthcare providers (HCPs) with patients at risk of non-adherence due to unexpected costs. The program, launched with a major pharmaceutical manufacturer, achieved over 200% growth in identified HCPs, leading to more than 46,000 additional prescriptions. The solution demonstrated a +6:1 return on investment and helped 27% of targeted HCPs enroll new patients. This advancement in predictive analytics showcases the company's ability to improve patient care and support HCPs effectively.

OptimizeRx Corp. (Nasdaq: OPRX) reported a 3% increase in revenue for Q2 2022, totaling $14.0 million, compared to $13.6 million in Q2 2021, largely due to new customer and program launches. Gross profit rose 12% year-over-year to $9.0 million. However, the company experienced a GAAP net loss of $3.9 million or ($0.21 per share). Cash and cash equivalents increased to $87.4 million. The updated 2022 revenue outlook anticipates $62 million to $68 million, marking 1% to 11% growth from 2021.

OptimizeRx Corp. (Nasdaq: OPRX) reported a 3% revenue increase to $14.0 million for Q2 2022, driven by new customers and program launches. Gross profit rose 12% year-over-year to $9.0 million, with a gross margin of 64%. However, the company faced a GAAP net loss of $3.9 million, significantly down from a profit of $0.4 million in the same quarter last year. Full year revenue guidance is updated to $62-$68 million, reflecting anticipated industry challenges. Cash reserves totaled $87.4 million as of June 30.

OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Cooler Screens to enhance healthcare advertising strategies through digital media platforms in retail pharmacies. This collaboration aims to boost patient engagement and improve access to affordable medications. Cooler Screens operates over 10,000 screens nationwide, reaching 90 million consumers monthly. The partnership enables agencies to utilize direct-to-consumer marketing strategies that enhance therapy adherence. The collaboration seeks to address the significant issue of medication affordability affecting 18 million Americans, highlighting the importance of accessible healthcare communication.

OptimizeRx Corp. (Nasdaq: OPRX) will host a conference call on August 9, 2022, at 4:30 p.m. Eastern time to discuss its second-quarter results for the period ending June 30, 2022. The financial results will be released prior to the call. The company emphasizes its commitment to enhancing patient engagement and medication adherence through its technology solutions, connecting over 60% of U.S. healthcare providers. Investors can access the call via the provided webcast link or telephone numbers.

OptimizeRx (Nasdaq: OPRX) has significantly enhanced its omni-channel platform through a partnership with Equals 5, providing access to up to 84% of prioritized healthcare providers (HCPs) on social media. This unique collaboration integrates real-world data and social media interaction, enabling targeted physician engagement. The Therapy Initiation and Persistence Platform now offers a true omni-channel reach, encompassing online, electronic health records, and social media platforms like Facebook and Instagram.

OptimizeRx Corp (Nasdaq: OPRX) has successfully integrated its TelaRep solution into its Therapy Initiation and Persistence Platform, enhancing connectivity for healthcare providers (HCPs). Launched in April 2020, TelaRep facilitates direct communication between HCPs and pharmaceutical representatives, now serving over 200,000 in-network providers. The solution’s effectiveness is exemplified by a 37% increase in prescriptions in specific territories. This development addresses the ongoing challenges faced by pharmaceutical sales forces and highlights the growing importance of digital communication in healthcare.

OptimizeRx Corp (Nasdaq: OPRX) announced its participation in three major conferences, including the 42nd Annual William Blair Growth Stock Conference in Chicago from June 6-9, the Stifel 2022 Cross Sector Conference in Boston from June 7-9, and the Roth Capital Partners 8th Annual London Conference from June 21-23. Each event will feature opportunities for management to present and hold one-on-one meetings with investors. OptimizeRx provides critical point-of-care technology solutions to enhance patient therapy adherence.